Ixensor Co

Ixensor Co Financing Cash Flow

The Net Financing Cash Flow of Ixensor Co (6734.TWO) as of Nov 5, 2026 is 31.68 M TWD. In the previous year, Net Financing Cash Flow was 50.31 M TWD — a change of -37.03% (lower).

Financing Cash Flow

31.68 MTWD

YoY

-37.03%

Last updated:

Net Financing Cash Flow of Ixensor Co is 2024 31.68 M TWD. Net Financing Cash Flow of Ixensor Co was 2023 50.31 M TWD. It decreases by -37.03% lower compared to the previous year.

The Ixensor Co Financing Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financing Cash Flow
Date
Financing Cash Flow
Jan 1, 2017
0.00 TWD
Jan 1, 2018
198.40 M TWD
Jan 1, 2019
11.01 M TWD
Jan 1, 2020
-2.42 M TWD
Jan 1, 2021
46.61 M TWD
Jan 1, 2022
24.89 M TWD
Jan 1, 2023
50.31 M TWD
Jan 1, 2024
31.68 M TWD
The Ixensor Co Financing Cash Flow history
YEARFinancing Cash FlowYoY
31.68 MTWD-37.03%
50.31 MTWD+102.15%
24.89 MTWD-46.60%
46.61 MTWD-2,026.91%
-2.42 MTWD-121.98%
11.01 MTWD-94.45%
198.40 MTWD—
0.00TWD-100.00%
305.00 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Ixensor Co Stock analysis

What does Ixensor Co do? iXensor Co., Ltd. generates revenue through its PixoTest Blood Glucose Monitoring System and ovulation detection system, targeting individuals managing diabetes and reproductive health. The company's technology platform measures biochemical parameters including blood sugar, luteinizing hormone, and cholesterol, providing data for diabetes management services. Its integrated medical device solutions serve customers seeking self-monitoring tools for chronic conditions and fertility tracking. The firm's products are designed for direct consumer use, with the PixoTest system offering blood glucose monitoring and the ovulation detection system supporting female hormone cycle management. These solutions leverage the company's platform to deliver personalized health insights without requiring third-party partnerships. The target segments include patients with diabetes and individuals tracking fertility cycles through biochemical monitoring. Ixensor Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ixensor Co stock

Net Financing Cash Flow of Ixensor Co is 31.68 M TWD in 2024.

Net Financing Cash Flow of Ixensor Co changed from 50.31 M TWD to 31.68 M TWD, representing a -37.03% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Financing Cash Flow Ixensor Co since 2006 – with annual values, charts, and detailed analysis.

Financing cash flow measures cash flows from debt issuance/repayment, equity transactions, and dividend payments.

Net Financing Cash Flow's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Financing Cash Flow's Ixensor Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Ixensor Co

All Key Metrics — Ixensor Co